Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

Completed

Conditions studied: Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis

In brief

The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs. In patients with cystic fibrosis (CF), this fungus is not known to cause damage to the lungs, but some patients respond with an allergic reaction that may cause wheeze, cough, or difficulty breathing. Approximately 230 patients will be enrolled with an additional 60 people who do not have CF and who do not have a history of asthma to serve as a comparison group.

Key facts

Study ID

NCT00585364

Run by

University of Pittsburgh

People needed

79

Starts

2005-03-01

Expected to finish

2010-12-01

Last updated by the study team

2016-02-15

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• (CF)
• diagnosis of CF
• age 6 years or older
• presence of A. fumigatus in culture of airway flora, or the presence of one or more of the diagnostic criteria for ABPA (Control)
• age and sex matched to CF population

You may not qualify if…

• (CF)
• uncontrolled CF-related diabetes mellitus
• use of oral steroids at a dose ≥ 0.5 mg/kg/day
• history of lung transplantation
• pulmonary exacerbation as defined by requirement for use of intravenous antibiotics or need for hospitalization within the preceding 14 days.
• patients who have a diagnosis of HIV and have a CD4+ Tcell count below 500 cells/ml will be excluded (control)
• asthma

Where it is running

• Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.